Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Neither. NYSE.
Nice call. About as bright as the Baker Bros riding AMRN from the low $20's to the $6's.
I'm sure that AVEO hiring a Senior Director of Tivozanib Marketing for the launch is all part of the scam.
https://www.aveooncology.com/director-sr-director-of-marketing/
Wealthy folks don't brag about their wealth. The sure sign of compulsive liars.
Quite the contrary. The foremost RCC oncologists like Dr. Rini and Dr. Pal would not associate themselves with "a scam going nowhere."
It is aggressively bullish. As they've dialed in the NDA to the refractory setting and have forfeited the front line mono therapy designation, I believe their approval chances are much better than 50-50. I'm thinking 75-25 with those PFS results they're putting up
Unfortunately, nano caps that constantly offer up new shares rarely play by the "should be" rules. It topped out at 42.50(split adjusted) in 2017 upon EMA approval. The shares outstanding at the time were 11.83M split adjusted and we now have 16.08M shares out,so it's been diluted 36%. So $42.50 less 36% = $27.20. But that 42.50 reflected the EMA/EUSA deal, which is and has always been just a royalty deal for AVEO. I think FDA acceptance could push this to the $60-$80 range on the pop, consolidating to $40-$50. Of course, this prediction is predicated on future dilution that is going to take place.
Great week to be short AVEO LOL. Up 75% in 5 days. Looks like you're the ass clown without a clue to me.
Nobody's buying, LOL. Just 20X normal volume yesterday. Dope.
Think real hard about this: More than half of the available shares on the street changed hands today resulting in a 25% gain.
AVEO will more likely be $14 on the FDA's acceptance of the NDA and Tivo's final HR of well under 1. In less than a year, this will be trading at $60 after the FDA approval. The script's already been written. Bayer's Nexavar will end up valued like a pile of dead flip phones in some recycling center.
You mean stocks don't just go straight up??? Shit, now you tell me. Anyway, I'll take 20%+ green that takes out the 200 MDA any day. Those RSI numbers are also pointing to a whole different outcome than what you're saying, ass clown.
Did you ever see Planes, Trains, & Automobiles?
"You're going the wrong way." LOL. Dope.
AVEO up 60% since the dark days of a month ago. Thought maybe Harry was onto something back then, but nope, the full on reversal and recovery is in full effect. You're either on the bus, off the bus, or under the bus like our favorite ass clown.
Yes Harry, I've been wondering why AVEO is only stock that's down over the past 2 months. You're so insightful.
Wrong again as the confirming SP reversal is well underway. You should have bailed on shorting AVEO like Fuerstein did a year ago.
Wrong again. The FDA will approve tivo for its superior performance in the refractory/relapsed setting. It's what they negotiated back in Nov to save both the face of Padzur and Bailey. So basically, once Bayer's patients are fed up with Sora's toxicity and its unremarkable effects on PFS, they can get Fotivda and feel better and live longer immediately.
Wrong. The median O/S is unmovable BUT the overall O/S continues to extend for Tivo vs Sora. No one wants the highly toxic, flip phone of cancer treatments anymore that Sora lamely offers. Not to mention Tivo's PFS continues to blow away Sora's. Bayer should actually rename Sora "Sorry'
The writing's on the wall. From MesaBoogie on ST:
"From October 2018 to August 2019, Sora was remarkably consistent: one-third of the nine patients on therapy discontinued therapy, one-third of those alive who had discontinued therapy died, and the overall number of deaths increased by one-third.
Tivo had only 1 of 34 (3%) on therapy discontinue treatment, but had 36% (comparable to Sora’s 33%)of patients who had discontinued therapy die, but the overall number of deaths increased by only 16%."
Fotivda approved for 1st line RCC treatment in Denmark.
https://medicinraadet.dk/anbefalinger-og-vejledninger/anbefalinger-nye-laegemidler-og-indikationsudvidelser/o-u-anbefalinger/tivozanib-fotivda
AVEO is days away from developing a coronavirus vaccine. They told me today that the vaccine will have FDA fast-track clearance. AVEO is about ready to bail out Trump's incompetence in allowing this virus to spread for 3 weeks while calling it a Dem hoax before finally reacting, too little,too late. He should have been proactive, but that requires rational thought.
There's toilet paper on your shoe
Dick....Head. I seriously hope you get cancer. What goes around, comes around. Karma has no pity.
US Steel down 10%, Boeing down 15%. Harry going down again into his pit of soullessness. I bet your Mom's so proud of you for pushing people's buttons during a national crisis. What a dick.
FDA approval coming for late line refractory RCC treatment. The deal was structured to save face for everyone following the 2013 debacle.
Just another impotent short. Kind of like cockroaches... Always around somewhere.
They already cut a deal on the NDA filing.
From MesaBoogie on ST, a guy who is very in tune with drug trials and outcomes.
"In case your trying to figure out the final OS HR, basically it's neck and neck as of August but the trend is in Tivo's favor. Basically four categories of "alive" patients left:
1. Progression Free and On Therapy:
Tivo has 20 of these patients. Because 31 Tivo patients had a 30% tumor reduction (response) and the median duration of response has not been met (i.e., of the 31 responders, the 16th patient to regress into disease hasn’t occurred) we know that at least 15 of the 20 on therapy have had their tumors shrink by at least 30%. They are highly likely to live from August 2019 to May 2020.
Sora has 2 of these patients. Enough said.
2. On Therapy following PFS Event:
These patients remain on therapy even though they had a PFS event (as death is not possible for this group, it is either disease progression or an interruption in therapy). If they are on therapy, it is a good sign they will live from August 2019 to May 2020.Tivo has 13 patients, Sora has 4.
3. Off Therapy But Alive
Most likely to die. Tivo has 25 of these patients, and Sora has 48. So, Sora’s “pool” of likely deaths is much larger than Tivo’s.
4. Off Therapy and Lost to Follow Up or Withdrew Consent to be Monitored
Tivo has 3 of these patients, and Sora 8.
I think AVEO located the LTFU patients, and the ones left in this category left the study and requested not to be monitored. AVEO is allowed, under FDA regulations, to check public records to determine survival status."
Again, enough said about Tivo vs Sora.
Ficlatuzamab is AVEO's dark horse, quietly garnering early positive combination trial results and an eye catching response rate and PFS data on treating pancreatic cancer.
https://www.bloomberg.com/press-releases/2020-01-27/aveo-oncology-and-biodesix-announce-results-from-phase-1b-study-of-ficlatuzumab-gemcitabine-and-nab-paclitaxel-in-advanced
I see the "Crew" had to send in FCY yesterday to shore up HC's ineptitude. LOL. Quite the pair.
Tivo is superior to Sora in every single way except O/S, which is maturing to be about the same. FDA approval coming, as European effectiveness of the drug that's already on the market is showing its superiority. Every oncologic publication is stating things like this: https://www.oncozine.com/tivozanib-improved-pfs-and-was-better-tolerated-compared-with-sorafenib-in-patients-with-mrcc/
But I'm sure 2 internet board trolls know better.
Here you go Harry. More BS, right? Look at the numbers and how they compare to your Jitterbug cancer treatment from Bayer:
https://content.iospress.com/articles/kidney-cancer/kca190073
Coming to an American pharmacy near you.
http://www.pharmatimes.com/news/nice_backs_eusas_kidney_cancer_drug_fotivda_1221446
That's all you got? So lame. This is clearly Tivozanib's year. Astra Zeneca and Bristol Meyers wouldn't be risking their good names with trials with a bad or risky drug
There are several ongoing combination trials and the final Tivo-3 mature data readout comes in Q2 after NDA gets filed this Q.
Tivozanib will pass ODAC and be granted FDA approval for refractory RCC. The deal has been structured to save Padzur's face after his vindictiveness 7 years ago against prior management who bucked his NDA recommendation. By going for the 2nd/3rd/4th lines this time, it has paved the way for easy approval. Sora passed the FDA because it was the first of it's kind and was only going against a placebo. It's now the flip phone of RCC treatment. The jewel of Tivozanib will be the combination therapies that are evolving across all lines. The drug works....and it works really really well, with less toxicities and twice the effective response rate as Sora. Thoughtful and insightful info like this is available on StockTwits by MesaBoogie who has a nice grasp on the topic. Or you could listen to the child here that LOL's all of the time about his crew from Mom's basement. You make the call.
And another recent article. The snowball is getting bigger and the float has been reduced 10-fold.
https://www.kcsn.org.uk/tivozanib-has-a-better-safety-profile-than-other-tkis-for-the-treatment-of-kidney-cancer/